Compare TMC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | TNGX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Canada | United States |
| Employees | 47 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | TMC | TNGX |
|---|---|---|
| Price | $4.34 | $19.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $9.06 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 6.1M | 2.7M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $2.15 | $1.04 |
| 52 Week High | $11.35 | $22.20 |
| Indicator | TMC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 57.07 |
| Support Level | $3.95 | $6.54 |
| Resistance Level | $4.89 | $22.01 |
| Average True Range (ATR) | 0.36 | 1.29 |
| MACD | 0.02 | -0.25 |
| Stochastic Oscillator | 34.40 | 33.33 |
TMC The Metals Co Inc is a deep-sea minerals exploration company focused on the collection, processing, and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ). Polymetallic nodules are discrete rocks that sit unattached to the seafloor, occur in notable quantities in the CCZ, and have high concentrations of nickel, copper, cobalt, and manganese in a single rock. The company believes these four metals contained in the polymetallic nodules are critical for energy infrastructure and industrial manufacturing. The Company's business consists of only one operating segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.